- Product Details
Keywords
- Ruxolitinib phosphate
- 1092939-17-7
- TIANFU CHEM Ruxolitinib phosphate
Quick Details
- ProName: Newblue CHEM Ruxolitinib phosphate
- CasNo: 1092939-17-7
- Molecular Formula: C17H18N6.H3PO4
- Appearance: White powder
- Application: Intermediates
- DeliveryTime: according to client's demand quantity
- PackAge: as requested
- Port: SHANGHAI
- ProductionCapacity: 100 Kilogram/Month
- Purity: 98%
- Storage: room temperature
- Transportation: by sea, by air or by courier
- LimitNum: 1 Kilogram
Superiority
Our company was built in 2009 with an ISO certificate.
In the past 5 years, we have grown up as a famous fine chemicals supplier in China and we had established stable business relationships with Samsung,LG,Merck,Thermo Fisher Scientific and so on.
Our main business covers the fields below:
1.Noble Metal Catalysts (Pt.Pd...)
2.Organic Phosphine Ligands (Tert-butyl-phosphine.Cyclohexyl-phosphine...)
3.OLED intermediates (Fluorene,Carbazole,Boric acid...)
4.Customs Synthesis
Our advantage:
1.Higest quality and good package
2.Fast delivery
3.Better payment term
4.Fast response to customer within 6 hours
5.Good business credit in Europe ,US ,Japan ,Korea
Details
Ruxolitinib phosphate Basic information
Product Name: Ruxolitinib phosphate
Synonyms: (betaR)-beta-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile phosphate;INCB 018424;Ruxolitinib, Phosphate Salt;Ruxolitinib, Phosphate;(βR)-β-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyriMidin-4-yl)-1H-pyrazole-1-propanenitrile Phosphate;INCB 018424(Ruxolitinib Phosphate);INCB 018424 (phosphate);INCB018424 (phosphate)
CAS: 1092939-17-7
MF: C17H18N6.H3PO4
MW: 404.360201
EINECS:
Product Categories: Intracellular signaling.;Antineoplastic;Inhibitors
Mol File: 1092939-17-7.mol
Ruxolitinib phosphate Usage And Synthesis
Uses The phosphate salt of Ruxolitinib (R702000). Ruxolitinib is a selective Janus tyrosine kinase (JAK1 and JAK2) inhibitor used in the treatment of myeloproliferative neoplasms and psoriasis.
Definition ChEBI: A phosphate salt obtained by reaction ruxolitinib with one equivalent of phosphoric acid. Used for the treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essent al thrombocythemia myelofibrosis.